鼻息肉治疗中度普利尤单抗使用与眼表不良事件无关联
基于FAERS数据库2019Q1至2022Q4数据,评估度普利尤单抗治疗慢性鼻窦炎伴鼻息肉(CRSwNP)相关眼表反应(DA-OSR)。CRSwNP组DA-OSR报告比值比(ROR)为0.84(0.73-0.97;p=0.015),不支持度普利尤单抗与CRSwNP治疗的眼表反应存在关联,而特应性皮炎(AD)组ROR为1.29(1.20-1.40;p<0.001)。
要点
- CRSwNP组DA-OSR的ROR为0.84(0.73-0.97;p=0.015),不支持与度普利尤单抗相关。
- AD组DA-OSR的ROR为1.29(1.20-1.40;p<0.001),证实与度普利尤单抗相关。
- CRSwNP治疗中年轻成人DA-OSR更多,无性别特异性倾向。
核心结论
- 本研究证实度普利尤单抗与AD治疗的眼表反应存在关联,但不支持度普利尤单抗与CRSwNP治疗的眼表反应存在关联。
- CRSwNP治疗中年轻成人经历更多DA-OSR,无性别特异性倾向。
研究设计与样本
- 使用FDA不良事件报告系统(FAERS)查询2019Q1至2022Q4期间的眼部反应报告,共60,198条观察记录,其中5,344条为CRSwNP治疗。
- 采用逻辑回归预测DA-OSR,并使用OpenVigil进行DA-OSR的不比例分析(DPA)。
主要发现
- DA-GOR和DA-OSR患病率以AD最高(15.3%,7.8%),其次为CRSwNP(12.2%,6.7%)和哮喘(9.2%,3.5%)。
- 最常见眼表反应为干眼(35.9%)、结膜炎(15.7%)和泪液分泌增多(11.0%)。
- CRSwNP治疗DA-OSR的ROR为0.84(0.73-0.97;p=0.015),AD为1.29(1.20-1.40;p<0.001),哮喘为0.66(0.59-0.73;p<0.001)。
- CRSwNP治疗中,男性DA-OSR的ROR为0.97(0.90-1.03;p=0.3),年龄>50岁老年人为0.78(0.73-0.83;p<0.001)。
- DPA中DA-OSR的ROR在任意适应症为12.5(12.2-12.8;p<0.001),仅CRSwNP治疗为0.58(0.53-0.64;p<0.001)。
局限性
- FAERS存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ocular surface reactions (OSR) have been associated with dupilumab for atopic dermatitis (AD) treatment. However, the association of dupilumab-associated OSR (DA-OSR) for nasal polyps (CRSwNP) treatment has not been studied. We evaluated DA-OSR for CRSwNP treatment using the FDA Adverse Event Reporting System (FAERS). METHODS: FAERS was queried for any general ocular reactions (DA-GOR) from 2019Q1 to 2022Q4. DA-OSR were subcategorized from DA-GOR and compared between treatment groups (CRSwNP, asthma, AD). Logistic regression was used to predict DA-OSR. Disproportionality analysis (DPA) of DA-OSR was performed using OpenVigil. RESULTS: There were 60,198 total observations, of which 5344 were treated for CRSwNP. The prevalence of DA-GOR and DA-OSR was greatest for AD (15.3%, 7.8%), followed by CRSwNP (12.2%, 6.7%) and asthma (9.2%, 3.5%). The most commonly reported OSRs were dry eyes (35.9%), conjunctivitis (15.7%), and increased lacrimation (11.0%). The reported odds ratio (ROR) of CRSwNP-treated DA-OSR was 0.84 (0.73-0.97; p = 0.015), compared to 1.29 (1.20-1.40; p < 0.001) for AD and 0.66 (0.59-0.73; p < 0.001) for asthma. For CRSwNP treatment, the DA-OSR ROR was 0.97 (0.90-1.03; p = 0.3) for men and 0.78 (0.73-0.83, p < 0.001) for older adults (age > 50). ROR in the DPA for DA-OSR was 12.5 (12.2-12.8; p < 0.001) for any indication and 0.58 (0.53-0.64; p < 0.001) for CRSwNP treatment only. CONCLUSIONS: While there are limitations to FAERS, this study confirms the association between dupilumab and OSR for AD treatment, and does not support an association between dupilumab and OSR for CRSwNP treatment. Younger adults experience more DA-OSR in CRSwNP treatment without a specific predilection for sex. LEVEL OF EVIDENCE: IV Laryngoscope, 134:2602-2608, 2024.
引用
- Swisher AR, Kshirsagar RS, Vu PQ, et al. Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment. Laryngoscope. 2023. PMID: 38038233. doi:10.1002/lary.31205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。